Therefore, although the current study provides meaningful findings in survival-related features of CD103+ immune cells across solid tumors and various materials used for assessment, it should be noted that the correlation between CD103+ immune cells and prognosis could vary among different tumor types. This evidence concerns the gene ITGAE and neoplasm.